Viewing nowPrebal Capsule 150mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Hanpoong Pharmaceutical Co., Ltd.

MFDS item code 201905663 · Approved 2019.08.12 · Insurance code 658107080
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also effective as an adjunct for partial seizures in patients with epilepsy, regardless of the presence of secondary generalized symptoms. Additionally, it is used to alleviate symptoms in patients with fibromyalgia, enhancing the quality of life for these patients. Overall, it is an effective medication for treating neuropathic pain, epilepsy, and fibromyalgia.
This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week, based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medication, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalinᵃ Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the administration regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Administration is not recommended in children under 12 years of age or adolescent patients aged 12-17 years because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, it is important to inform the healthcare provider immediately if symptoms of depression or mood changes occur during use. Patients with allergies to any components of this medication should avoid taking it, and those with lactose intolerance should also avoid this medication. Patients with diabetes may be affected in blood sugar control due to weight gain, so they should discuss dosage adjustments with their physician. If symptoms of angioedema occur, discontinue use immediately and consult with a healthcare professional. Elderly patients should be careful to avoid falls due to dizziness or drowsiness and should be cautious until they are accustomed to the medication. Temporary blurred vision or changes in vision may occur, and if symptoms are severe, consideration should be given to discontinuing the medication. Stopping the medication suddenly may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety; therefore, it should be reduced gradually in consultation with a healthcare provider. Due to the risk of medication abuse, patients with a history of drug abuse should be particularly careful. Patients with impaired kidney function must have their dosages adjusted, and those with heart disease should use caution. When taken with other medications that have central nervous system depressant effects, the risk of side effects such as respiratory depression may be increased, hence caution is advised. In early pregnancy, this medication may pose risks to the fetus, so pregnant women should avoid taking this medication, and women of childbearing age should use effective birth control methods. Women who are breastfeeding should consult with healthcare professionals about discontinuing breastfeeding or the medication, as this drug could be passed into breast milk. Activities such as driving or operating machinery should be avoided until dizziness or drowsiness resolves after taking this medication. In case of overdose, confusion, drowsiness, or depression may occur, so immediate emergency treatment is required. This medication should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and light exposure, and it is recommended to store it at room temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.
A white hard capsule containing white powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Hanpoong Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.